louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06002256: Mostafa Maged Maneuver in Comparison With Bimanual Uterine Compression to Control Post-partum Hemorrhage
Official title: Mostafa Maged Maneuver in Comparison With Bimanual Uterine Compression to Control Post-partum Hemorrhage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post-partum Hemorrhage
Keywords: Mostafa Maged maneuver
Bimanual uterine compression
vaginal delivery
postpartum hemorrhage
Lead sponsor: Ministry of Health and Population, Egypt
Sponsor class: OTHER_GOV
Collaborators: name: Al-Azhar University
First posted: 2023-08-21
Enrollment: 200
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current study aimed to investigate the effectiveness of the Mostafa Maged maneuver compared to Bimanual uterine compression in controlling postpartum hemorrhage during vaginal delivery.

The study subjects were categorized into two groups. The first group was managed by the Mostafa Maged maneuver , whereas the second group was managed by routine bimanual uterine compression.

investigators attempted to determine the duration of each maneuver required until the investigator became exhausted, as well as whether or not oxytocin was administered later in each maneuver .


Eligibility criteria: Inclusion Criteria:

- female and pregnant

Exclusion Criteria:

* hematological diseases morbid obese smoking

Primary outcomes:
measure: Good hemostasis and achieving the uterus contracted
timeFrame: first 3 hours
measure: obstetrician does not feel fatigued
timeFrame: during applying the maneuver
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Fayoum general hospital and al azhar university
state: Cairo And Fayoum
Study officials:
References:
Clinical trial NCT00570856: Trial of Folic Acid Effect on Hcy and cIMT After Kidney Tx
Official title: Clinical Trial of Effectiveness of Folic Acid Therapy on Homocysteine Level and Carotid Intima-Media Thickness After Kidney Transplantation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Kidney Transplantation
Keywords: Folic Acid
Homocysteine
intima-media thickness
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2007-12-11
Enrollment: 60
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: To see the effect of Folic acid supplementation after kidney transplantation on plasma total homocysteine level and carotid intimal-media thickness


Eligibility criteria: Inclusion Criteria:

* having hyperhomocysteinemia(tHcy\>12.5 µmol/L in men and 11.5 µmol/L in women )
* No evident history of CVD 4. no evidence of cigarette smoking
* not participating in other clinical studies on evaluation of cardiac diseases and
* not taking any lipid lowering treatment
* not being pregnant or breast feeding a baby(women)
* Having HIV or viral hepatitis infections.

Exclusion Criteria:

* unstable condition of the transplanted kidney (Cr\> 3 mg/dl, BUN \> 50 mg/dl)
* Cyclosporine (CsA) intoxication
* New onset of any severe disease ( such as MI, stroke, DM, etc.).

Primary outcomes:
measure: plasma level of total homocysteine (tHcy)
timeFrame: 6 months
Secondary outcomes:
measure: carotid intima-media thickness (cIMT)
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Urology Nephrology Research Center, Labbafi Nejad Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
name: Mohsen Nafar, MD- Nephrologist
role: STUDY_CHAIR
affiliation: Labbafi Nejad Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
name: Farideh Khatami, Master of Science
role: PRINCIPAL_INVESTIGATOR
affiliation: Urology Nephrology Research Center, Labbafi Nejad Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
name: Babak Kardavani, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00713856: Comparison of Conventional and Custom Photorefractive Keratectomy (PRK)
Official title: Comparison of Conventional and Custom With Iris Registration PRK Ablations: Assessment of Visual Function and Patient Satisfaction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myopia
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2008-07-14
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study objective is to compare the clinical outcomes using wavefront guided PRK with iris registration and conventional laser PRK using FDA-approved laser technology on the same patient.

Detailed description: Patients undergoing bilateral PRK on the same day will have one eye randomly assigned to custom wavefront guided PRK and the fellow eye treated with conventional PRK.

Eligibility criteria: Inclusion Criteria:

* Patients deemed to be suitable candidates for bilateral PRK

Exclusion Criteria:

* Patients desiring monovision correction rather than bilateral distance correction

Primary outcomes:
measure: Visual acuity
timeFrame: 6 months
Secondary outcomes:
measure: Manifest refraction
timeFrame: 6 months
measure: Wavefront aberration value
timeFrame: 6 months
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah, John Moran Eye Center
state: Utah
Study officials:
affiliation: University of Utah
name: Mark Mifflin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05081856: Use Modular Medical Equipment Vehicle in Mobilization of Patient With Chest Tube
Official title: The Effect of Modular Carrying System on Patient Outcomes in the Mobilization of Patients With a Chest Tube
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mobility Limitation
Sleep Quality
Pain
Comfort
Time of the Removal Chest Tube
Keywords: care outcomes
mobilization
chest tube
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2021-10-18
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Interventional study with posttest control group
Primary purpose: OTHER

Brief summary: in this study, it was aimed to examine the effect of the modular carrying system on the outcomes of care in the mobilization of patients with a chest tube. The population of the study consisted of patients followed in Yedikule Chest Diseases, and Thoracic Surgery Training and Research Hospital between October 2019 and January 2021, and the sample consisted of 83 patients who met the inclusion criteria. The study was performed with the intervention group (n=37) mobilized with the Modular medical equipment carrying vehicle and the control group (n=46) mobilized with the routine application.

Detailed description: Within the scope of the study, a Modular medical equipment carrying vehicle was developed by the researchers to ensure the safe and comfortable mobilization of patients with chest tube and additional medical equipment. This vehicle has been designed to maintain the level of the chest tube during mobilization and to prevent it from tipping over.Patients in the intervention group were mobilized with the help of this Modular medical equipment carrying vehicle for 20 minutes at least 6 times a day. Patients in the control group were mobilized at least 6 times a day for 20 minutes with clinical routine practice.

Eligibility criteria: Inclusion Criteria:

* chest tube inserted due to open surgery, hemodynamically stable, followed up in the clinic for at least 5 days, first mobilized after chest tube inserted

Exclusion Criteria:

* have a mental or psychological illness, hemodynamically unstable

Primary outcomes:
measure: general comfort scale score
timeFrame: first day and fifth day
measure: Richard Campell sleep quality scale score
timeFrame: every day for five days
measure: pain scale score
timeFrame: every day for five days
measure: patient mobility scale score
timeFrame: every day for five days
measure: drain removal time (day (median))
timeFrame: the day the drain was removed
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
Study officials:
affiliation: Medipol University
name: Pınar Dogan, Asst.Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05274256: Implant Placement in Horizontally Deficient Maxillary Aesthetic Zone With Simultaneous Soft Tissue Augmentation
Official title: Implant Placement in Horizontally Deficient Maxillary Aesthetic Zone With Simultaneous Soft Tissue Augmentation Using De-epithelialized Free Gingival Graft and Its Effect on Esthetics. a Case Series Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Implant or Graft; Rejection
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-03-10
Enrollment: 11
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Tooth extraction in maxillary esthetic zone is accomplished with great dimensional changes of the alveolar ridge, different procedures have been tested to compensate these dimensional alteration, such as Hard bone augmentation, Soft tissue augmentation Or augmentation of both together. Hence, the present study aimed to evaluate pink esthetic score, clinical implant stability and bucco-palatal dimensional changes in the maxillary esthetic zone treated by implant placement with simultaneous soft tissue augmentation using de-epithelialized free gingival graft.


Eligibility criteria: Inclusion Criteria:

* Patient of both sexes with missing teeth in the maxillary aesthetic zone.

Exclusion Criteria:

* Patients with systemic disease that may affect bone quality or bone healing.

Primary outcomes:
measure: pink esthetic score
timeFrame: 6 month
Secondary outcomes:
measure: Implant stability quotient
timeFrame: 6 month
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT04587856: Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
Official title: Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Myelodysplastic Syndromes
Lead sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.

Detailed description: This is a biological study for adult MDS patients who undergo HSCT procedure.The research is focused on the study of biological mechanisms of disease relapse after HSCT in MDS to provide the rationale to develop pre-emptive strategies in patients with high risk of transplant failure.

Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence.

CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant by using Single-cell sequencing.

To study genomic and transcriptomic changes in CD34+ blast cells at disease relapse after HSCT will be used TARGET-seq in parallel with unbiased whole-transcriptome analysis.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of MDS according to 2016 WHO criteria
* Aged 18y or older
* Patients who will receive allogeneic stem cell transplantation (HSCT)
* Signed written informed consent according to ICH/EU/GCP and national local laws

Exclusion Criteria:

* Second HSCT procedure.

Primary outcomes:
measure: CD34+ blast cells modifications
timeFrame: at 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bari
country: Italy
facility: Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
city: Firenze
country: Italy
facility: Unità di Ricerca e di Malattie del sangue - Ematologia S. Luca Vecchio
city: Genova
country: Italy
facility: AOU San Martino-IST-Ematologia 1
city: Perugia
country: Italy
facility: Sezione di Ematologia - Ospedale S.Maria della Misericordia
city: Roma
country: Italy
facility: Dip. di Medicina Trasl. E di Precisione - U.O.C. Ematologia
city: Roma
country: Italy
facility: Policlinico Tor Vergata
city: Rozzano
country: Italy
facility: Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia
Study officials:
References:
Clinical trial NCT05600556: Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)
Official title: The Role of Virtual Reality (VR) in Patient Experience When Used for Magnetic Resonance-Guided Radiation Therapy (MRgRT)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2022-10-31
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This clinical trial explores if using virtual reality (VR) headsets will help to improve patient understanding of their disease and decrease anxiety about treatment. Three-dimensional (3D) images may help the patient visualize their tumor and location better and therefore understand potential side effects. Visualizing a virtual representation of the magnetic resonance imaging (MRI) linear accelerator (Linac) may decrease treatment related anxiety.

Detailed description: PRIMARY OBJECTIVE:

I. Examine patient reported comprehension of their tumor characteristics and treatment plan following 3D virtual reality review of their imaging.

SECONDARY OBJECTIVE:

I. Examine patient reported treatment related anxiety prior to and following virtual reality (VR) simulation of the MRI Linac treatment process.

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT I: Patients receive two-dimensional (2D) image review using standard computer screen on study. Patients undergo MRI and computed tomography (CT) imaging at screening and on study.

COHORT II: Patients receive image review using virtual reality stimulation on study. Patients also view MRI treatment room using virtual reality stimulation. Patients undergo MRI and CT imaging at screening and on study.

Eligibility criteria: Inclusion Criteria:

* Age: above 18 years
* Participants must be histologically proven neoplasm
* Planned to undergo radiation treatment using the MR Linac

Exclusion Criteria:

* Inability to tolerate virtual reality headset
* Non-English speaking patients
* Pediatric patients are ineligible

Primary outcomes:
measure: Increase in composite knowledge questionnaire score
timeFrame: At Baseline
measure: Increase in composite knowledge questionnaire score
timeFrame: At first on treatment visit (after starting radiation)
Secondary outcomes:
measure: General anxiety
timeFrame: At Baseline
measure: General anxiety
timeFrame: At first on treatment visit (after starting radiation)
measure: MRI specific anxiety
timeFrame: Baseline and after MRI scan at time of planning scan
measure: Plan review understanding
timeFrame: Baseline and at first on treatment visit (after starting radiation)
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Sidney Kimmel Cancer Center at Thomas Jefferson University
state: Pennsylvania
Study officials:
affiliation: Thomas Jefferson University
name: Adam Mueller, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01326156: Study of Knee Replacements for Patellofemoral Osteoarthritis
Official title: Patellofemoral Arthroplasty (PFA) Versus Total Knee Replacement (TKR) for Isolated Patellofemoral Osteoarthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteoarthritis, Knee
Keywords: Osteoarthritis
Knee
Knee cap
Patella
Patellofemoral
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Stryker Nordic
name: DePuy Orthopaedics
First posted: 2011-03-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized comparison of PFA and TKR in treatment of isolated patellofemoral osteoarthritis.

Detailed description: Isolated patellofemoral osteoarthritis can be a disabling condition of the knee necessitating knee arthroplasty. It is debated whether total knee replacement or isolated patellofemoral replacement is the better treatment option. This randomized trial attempts to give a qualified answer to the debate by comparing clinical outcome (range of movement, stability, effusion, patellofemoral tracking, tenderness, stair climbing), patient self assessment scores (EQ-5D, Oxford Knee Score, KOOS, SF-36, AKS), complications (infections, revisions), longevity (survival analysis) and cost (direct and indirect) for the two implant types.

The Avon patellofemoral implant has been chosen, as this is the patellofemoral implant with the best documentation. The PFC Sigma CR total knee implant has been chosen as it a current standard implant and market leader.

Eligibility criteria: Inclusion Criteria:

* Isolated PF-OA

Exclusion Criteria:

* Medial or lateral OA

Primary outcomes:
measure: Patient-reported outcomes (disease-specific and generic QoL instruments)
timeFrame: 10 years
Secondary outcomes:
measure: Implant survival, clinician assessment and cost.
timeFrame: 10 years
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
affiliation: Dept. of Orthopaedics, Aarhus University Hospital
name: Anders Odgaard, FRCS, DMSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Odgaard A, Kappel A, Madsen F, Kristensen PW, Stephensen S, Attarzadeh AP. Patellofemoral Arthroplasty Results in Better Time-weighted Patient-reported Outcomes After 6 Years than TKA: A Randomized Controlled Trial. Clin Orthop Relat Res. 2022 Sep 1;480(9):1707-1718. doi: 10.1097/CORR.0000000000002178. Epub 2022 Mar 21.
Clinical trial NCT03966456: Real World Study of Four PD-1 Agents in China
Official title: Real World Study of Immunotherapy-Comparison of Four PD-1 Agents in China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thoracic Cancer
Gynecologic Cancer
Abdomen Tumors
Malignant Melanoma
Lead sponsor: The Affiliated Hospital of Qingdao University
Sponsor class: OTHER
First posted: 2019-05-29
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients treated with PD-1 agents (nivolumab, pebrolizumab, toripalimab, sintilimab)

Brief summary: Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Detailed description: Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）

Eligibility criteria: Inclusion Criteria:

* Patients with lung cancer, liver cancer and other solid cancers
* Histologically or cytologically confirmed diagnosis cancer treated with PD-1 agents
* At least one measurable lesion
* Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1 Adequate organ function

Exclusion Criteria:

* patients treated with PD-1 agents less than 2 terms

Primary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: 1 year
Secondary outcomes:
measure: Number of Participants Experiencing Adverse Events (AEs)
timeFrame: 1 year
Other outcomes:
measure: PFS
timeFrame: 2 years
Locations:
city: Qingdao
country: China
facility: The Affiliated Hospital of Qingdao University
state: Shandong
Study officials:
affiliation: The Affiliated Hospital of Qingdao University
name: Xiaochun Zhang, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00711256: Sunscreen: Persistence of Sun Protection Factor and the Influence on Vitamin D
Official title: Sunscreen Removal by Clothing Meassured in Vivo. Sun Protection Factor Persistence During a Day Indoor Without Physical Activity. Does Sunscreen Reduce Vitamin D?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vitamin D Production in the Skin
Sunscreen Persistence
Keywords: Sunscreen
Application
Vitamin D
Sun protection factor
Clothing
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
First posted: 2008-07-08
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: The investigators want to investigate whether sunscreen is removed by clothing and to what extend when the amount of sunscreen applied varies.Does clothing reduce the SPF when clothes are put on 20, 8, or 4 minutes after sunscreen application? The investigators also want to investigate the persistence of sunscreen during eight hours indoor. How much does the SPF reduces? Furthermore, we want to investigate whether sunscreen in the layers 2, 1, and 0.5 mg/cm2 reduce the vitamin D production in the skin.


Eligibility criteria: Inclusion Criteria:

* Healthy participants.
* \> 18 years.
* Skin type I, II, and III.

Exclusion Criteria:

* Pregnancy.
* Medicin use.
* Skin or other diseases.
* The participants must not have been in solarium or gotten sun on their trunks in the 3 months before the study start and during the study.
* Skin types IV and above.

Primary outcomes:
measure: vitamin D (nmol) meassured in a blood sample.
timeFrame: 5 days after sunscreen use and UV light exposure
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Bispebjerg Hospital
state: Kbh Nv
Study officials:
References:
citation: Beyer DM, Faurschou A, Philipsen PA, Haedersdal M, Wulf HC. Sun protection factor persistence on human skin during a day without physical activity or ultraviolet exposure. Photodermatol Photoimmunol Photomed. 2010 Feb;26(1):22-7. doi: 10.1111/j.1600-0781.2009.00479.x.